These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 27606448)

  • 1. Merck stakes out 'irritable' neuron territory with $1.25 billion.
    Sheridan C
    Nat Biotechnol; 2016 Sep; 34(9):900. PubMed ID: 27606448
    [No Abstract]   [Full Text] [Related]  

  • 2. The effect of gefapixant, a P2X3 antagonist, on cough reflex sensitivity: a randomised placebo-controlled study.
    Morice AH; Kitt MM; Ford AP; Tershakovec AM; Wu WC; Brindle K; Thompson R; Thackray-Nocera S; Wright C
    Eur Respir J; 2019 Jul; 54(1):. PubMed ID: 31023843
    [TBL] [Abstract][Full Text] [Related]  

  • 3. P2X3 receptor antagonist (AF-219) in refractory chronic cough: a randomised, double-blind, placebo-controlled phase 2 study.
    Abdulqawi R; Dockry R; Holt K; Layton G; McCarthy BG; Ford AP; Smith JA
    Lancet; 2015 Mar; 385(9974):1198-205. PubMed ID: 25467586
    [TBL] [Abstract][Full Text] [Related]  

  • 4. P2X3-Receptor Antagonists as Potential Antitussives: Summary of Current Clinical Trials in Chronic Cough.
    Dicpinigaitis PV; McGarvey LP; Canning BJ
    Lung; 2020 Aug; 198(4):609-616. PubMed ID: 32661659
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gefapixant: First Approval.
    Markham A
    Drugs; 2022 Apr; 82(6):691-695. PubMed ID: 35347635
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Update on the clinical development of gefapixant, a P2X3 receptor antagonist for the treatment of refractory chronic cough.
    Muccino D; Green S
    Pulm Pharmacol Ther; 2019 Jun; 56():75-78. PubMed ID: 30880151
    [TBL] [Abstract][Full Text] [Related]  

  • 7. P2X3 receptor antagonist in chronic cough.
    Turner RD; Rajakulasingam RK; Bhowmik A; Bothamley GH
    Lancet; 2015 Jul; 386(9990):244. PubMed ID: 26194521
    [No Abstract]   [Full Text] [Related]  

  • 8. The therapeutic potential of purinergic signalling.
    Burnstock G
    Biochem Pharmacol; 2018 May; 151():157-165. PubMed ID: 28735873
    [TBL] [Abstract][Full Text] [Related]  

  • 9. P2X7 antagonists for CNS indications: recent patent disclosures.
    Pevarello P; Bovolenta S; Tarroni P; Za L; Severi E; Torino D; Vitalone R
    Pharm Pat Anal; 2017 Mar; 6(2):61-76. PubMed ID: 28248151
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The P2X7 receptor: A main player in inflammation.
    Adinolfi E; Giuliani AL; De Marchi E; Pegoraro A; Orioli E; Di Virgilio F
    Biochem Pharmacol; 2018 May; 151():234-244. PubMed ID: 29288626
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Update on novel purinergic P2X3 and P2X2/3 receptor antagonists and their potential therapeutic applications.
    Marucci G; Dal Ben D; Buccioni M; Martí Navia A; Spinaci A; Volpini R; Lambertucci C
    Expert Opin Ther Pat; 2019 Dec; 29(12):943-963. PubMed ID: 31726893
    [No Abstract]   [Full Text] [Related]  

  • 12. Deal watch: Merck bets on purine receptor revival.
    Cully M
    Nat Rev Drug Discov; 2016 Aug; 15(8):525. PubMed ID: 27444222
    [No Abstract]   [Full Text] [Related]  

  • 13. Involvement of the P2X7 purinergic receptor in inflammation: an update of antagonists series since 2009 and their promising therapeutic potential.
    Baudelet D; Lipka E; Millet R; Ghinet A
    Curr Med Chem; 2015; 22(6):713-29. PubMed ID: 25515510
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Extracellular Adenosine 5'-Triphosphate in Obstructive Airway Diseases.
    Pelleg A; Schulman ES; Barnes PJ
    Chest; 2016 Oct; 150(4):908-915. PubMed ID: 27568579
    [TBL] [Abstract][Full Text] [Related]  

  • 15. P2X7 antagonists as potential therapeutic agents for the treatment of CNS disorders.
    Chrovian CC; Rech JC; Bhattacharya A; Letavic MA
    Prog Med Chem; 2014; 53():65-100. PubMed ID: 24418608
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The evolution of P2X7 antagonists with a focus on CNS indications.
    Rech JC; Bhattacharya A; Letavic MA; Savall BM
    Bioorg Med Chem Lett; 2016 Aug; 26(16):3838-45. PubMed ID: 27426304
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The stain wars.
    Olsson GO; Blasetto JW; Bryzinski BS; Caplan RJ; Gold A
    Lancet; 2003 Nov; 362(9398):1855-6; discussion 1856. PubMed ID: 14654329
    [No Abstract]   [Full Text] [Related]  

  • 18. Purinergic Signalling and Neurological Diseases: An Update.
    Burnstock G
    CNS Neurol Disord Drug Targets; 2017; 16(3):257-265. PubMed ID: 27658510
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Motor neuron dysfunction in a mouse model of ALS: gender-dependent effect of P2X7 antagonism.
    Cervetto C; Frattaroli D; Maura G; Marcoli M
    Toxicology; 2013 Sep; 311(1-2):69-77. PubMed ID: 23583883
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The statin wars.
    McKillop T
    Lancet; 2003 Nov; 362(9394):1498. PubMed ID: 14602449
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.